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INTRODUCTION
Primary non-Hodgkin’s lymphoma of bone (PLB) is a
rare disease that accounts for less than 2 percent of all lym-
phomas in adults (1). The histologies of the vast majority of
cases present as diffuse large B-cell lymphoma, while T-cell
lymphomas are extremely rare (2-10). Although there are a
few publications regarding the characteristics, treatment
options, and prognosis of PLB, the optimal management
remains unclear. Recently, several reports have supported
the combined modality of chemotherapy and radiotherapy
(11-13). Multiple myeloma is a B-cell neoplasia that is usu-
ally associated with osteolytic lesions and paraprotein in the
plasma and/or in the urine (14-16). Because of the uniquely
different cell lines of the two lymphoid malignancies, con-
current disease has rarely been reported. To our knowledge,
the simultaneous development of primary T-cell lymphoma
of bone and multiple myeloma has never been reported. In a
view of the same bone lesion in the case of PLB and multi-
ple myeloma, the clinical discrimination of the two diseases
is difficult. Through this case, we experienced the importance
of reevaluation of disease regarding the possibility of other
underlying diseases when it was deteriorated despite ade-
quate treatment. 
CASE REPORT
A 48-yr-old male presented with right ankle pain, mass,
and general weakness over 2 months. On physical examina-
tion, he appeared acutely ill but no other specific findings
were noted.
The complete blood cell counts showed leucocytes 8.7×
109/L, hemoglobin 15.5 g/dL, and platelets 245×109/L.
Blood chemistry showed total protein 6.6 g/dL, albumin
4.6 g/dL, lactate dehydrogenase 236 U/L, blood urea nitro-
gen 14.2 mg/dL, and creatine 0.9 mg/dL. Urinalysis was
normal. Simple radiography showed an osteolytic lesion in
the right distal tibia. Magnetic resonance imaging (MRI) of
the right ankle revealed a heterogeneous osteolytic and ext-
raosseous mass in the right tibia (Fig. 1A, B). The bone biopsy
showed diffuse infiltration of large tumor cells with vesicu-
lar prominent nuclei, abundant cytoplasm, and numerous
mitotic figures. Immunohistochemical staining showed an
LCA, CD3, CD45RO, and CD15 phenotype (Fig. 2). These
findings led to the diagnosis of a T-cell lymphoma. We then
performed the staging work-up. Chest and abdomen com-
puted tomography (CT) showed no abnormal findings such
as lympadenopathy or hepatosplenomegaly. The Tc99m-methy-
lene diphosphonate (MDP) bone scan revealed hot uptake in
the right distal tibia without any other bony involvement
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Newly Developed Multiple Myeloma in a Patient with Primary T-Cell
Lymphoma of Bone
Primary non-Hodgkin’s lymphoma of bone (PLB) is rare, and generally presents
as a single extensive and destructive bone lesion. Histopathologically, most cases
present as diffuse large B-cell lymphoma, and T-cell lymphoma is rare. By contrast,
multiple myeloma is a disease defined as the neoplastic proliferation of a single
clone of plasma cells producing a monoclonal immunoglobulin. We report a case
of multiple myeloma that developed during treatment of PLB in a type of T-cell. A
48-yr-old man was diagnosed as T-cell PLB, stage IE, 18 months ago. The patient
received the chemoradiotherapy and salvage chemotherapy for PLB. However,
the lymphoma progressed with generalized bone pain, and laboratory findings
showed bicytopenia and acute renal failure. On bone marrow biopsy, the patient
was diagnosed as having multiple myeloma newly developed with primary T-cell
lymphoma of bone. In spite of chemotherapy, the patient died of renal failure.
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(Fig. 1C). The peripheral blood smear was normal, and the
bone marrow biopsy showed no lymphoma involvement.
The patient was diagnosed as having primary T-cell lym-
phoma of bone, stage IE. Based on the International Prog-
nostic Index, the patient belonged to a low risk group (17).
The patient received 6 cycles of CHOP chemotherapy
(cyclophosphamide 750 mg/m2 i.v. day 1, doxorubicin 50
mg/m2 i.v. day 1, vincristine 1.4 mg/m2 i.v. day 1, and pred-
nisolone 100 mg p.o. days 1-5). Follow-up MRI showed a
partial response. After addition of the involved-field radia-
tion therapy up to 5,700 cGy as once daily fraction and two
more cycles of chemotherapy, the tumor mass was further
decreased, but still remained on MRI. F-18 fluorodeoxyglu-
cose PET-CT showed the remaining hypermetabolic lesion
on tibia, and also revealed hot uptake at the inferior ramus
of the right pubis (Fig. 3A). We thought that the disease was
progressive and treated the patient with salvage chemother-
apy including ICE regimen (ifosfamide 5 g/m2 i.v. day 2,
and carboplatin AUC of 5 i.v. day 2, and etoposide 100 mg/
m2 i.v. days 1-3) and the DHAP regimen (dexamethasone
40 mg i.v. days 1-4, cytarabine 2 g/m2 i.v. day 2, and cisplatin
100 mg/m2 i.v. D1), but the disease further progressed. The
patient received the MINE regimen (ifosfamide 1,333 mg/
Fig. 1. Simple radiography showed oste-
olytic lesions in the right distal tibia (A).
Magnetic resonance imaging (MRI) of
the right ankle revealed a heterogeneous,
extraosseous mass in the right tibia (B).
The Tc-99m bone scan revealed diffuse
hot uptake in the right tibia without any
other bony involvement at the time of
diagnosis of lymphoma (C). A B C
Fig. 2. Diffuse infiltration of large tumor cells with vesicular prominent nucleoli, abundant cytoplasm, and numerous mitotic cells (A, H&E,
×200). Immunohistochemical staining for CD45RO showed positive (B, ×200).
A B
Fig. 3. After chemoradiotherapy, F-18 FDG PET-CT showed the
residual hypermetabolic lesion on tibia, but also revealed hot up-
takes at the inferior ramus of the right pubis (A). Despite salvage
chemotherapy, F-18 FDG PET-CT revealed diffuse hot uptake in
a skeletal area (B). 
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m2 i.v. days 1-3, mitoxanthrone 8 mg/m2 i.v. day 1, and etopo-
side 65 mg/m2 i.v. days 1-3) as the fourth line chemothera-
py. After three cycles of MINE chemotherapy, restaging
work-up showed a partial response. However, at the time of
the fourth chemotherapy cycle, he complained of generalized
bone pain. Complete blood cell counts revealed bicytopenia
(leucocytes 4.5×109/L, hemoglobin 8.8 g/dL, platelets 85×
109/L), and the peripheral blood smear showed atypical lym-
phocytes (2%). Serum creatine was 2.0 mg/dL. Whole body
PET revealed multiple hot uptake in the skeletal area (Fig.
3B). Unexpectedly, the bone marrow biopsy showed diffuse
infiltration of plasma cells with about 80% of bone marrow
cells. Monoclonal gammopathy was detected in urine pro-
tein electrophoresis. Urine immunoelectrophoresis identi-
fied the monoclonal band as light chain lambda, and the free
serum light chain lambda level in urine was 2,810 mg/L
(range, 5.71-26.3 mg/L). Bone marrow biopsy showed dif-
fuse uptake of CD138, which was not expressed in the lym-
phoma mass (Fig. 4). We concluded that the multiple myelo-
ma was newly developed in the patient with primary T-cell
lymphoma of bone. The general condition of the patient
was rapidly deteriorated with thrombocytopenia and acute
renal failure. The patient received a combination chemother-
apy with cyclophosphamide and prednisolone, and plasma-
pheresis was performed to correct paraproteinemia and hyper-
calcemia. Despite aggressive supportive care, the patient
died of renal failure.
DISCUSSION
PLB generally presents as a solitary, extensive, destructive
bone lesion (1). It is a very rare disease that accounts for less
than 2 percent of all lymphomas in adults and accounts for
approximately 3-5% of all malignant bone tumors and 4-
7% of all extranodal non-Hodgkin’s lymphomas. Patholog-
ic fracture and systemic ‘B’ symptoms (fever, weight loss,
and night sweats) also develop at the time of diagnosis (4,
5). Most patients suffer from bone pain, which is not relieved
by rest. A palpable mass due to soft tissue extension is seen
in about one-half of cases (10). It is usually characterized by
lytic bones lesions located in the metaphysis of long bones
or in the axial skeleton (2-7). Histologic diagnosis may be
obtained by percutaneous or open biopsy. Histopathologi-
cally, the majority of PLB are diffuse large B-cell type, while
T-cell lymphomas are extremely rare (4-7). Management strate-
gies include a combined modality of chemotherapy and radio-
therapy (11-13). Although prognosis, survival, and complete
remission rates of B-cell PLB were well-described and high
complete remission rates have been reported, the treatment
response and prognosis of T-cell PLB remain obscure and
data are lacking (7-9).
Multiple myeloma is a lymphoproliferative disease as is
lymphoma (14). It is characterized by the neoplastic prolifer-
ation of a single clone of plasma cells producing a monoclon-
al immunoglobulin. This clone of plasma cells proliferates
in the bone marrow and often results in skeletal osteolytic
lesions. Common clinical features include recurrent bacteri-
al infection, anemia, hypercalcemia, and renal insufficiency,
and treatments include chemotherapy and radiotherapy (16).
An interesting feature of this case is the development of
multiple myeloma over approximately 1.5 yr following the
appearance of a primary T-cell lymphoma of bone. He suf-
fered from two lymphoid neoplasms of distinctly different
cell lines: the first originating from T-cells and, 1.5 yr later,
the second of B-cell origin. Bryant et al. reported plasma
cell myeloma in a patient with a cutaneous T-cell lymphoma
(17). The investigators assumed that the malignant plasma
cells evolved under the sustained inducer stimulus of the
neoplastic T-cells. Wickenhauser et al. also reported a newly-
detected multiple myeloma in a patient with a long-stand-
ing anaplastic cutaneous T-cell lymphoma (20). In the pre-
sent case, through immunohistochemical CD138 staining,
we confirmed that the multiple myeloma originated from
Fig. 4. CD138 expression in the lymphoma mass (A) and bone marrow biopsy at the diagnosis of multiple myeloma (B) (×200).
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cells that differed from previously detected lymphoma cells.
Neoplastic T-lymphocytes are known to retain immunoreg-
ulatory capabilities similar to those of their normal counter-
part (18, 19). We also speculated that the proliferation of T-
helper cells might have resulted in a sustained stimulation
of B-cells, followed by proliferation of certain B-cell clones.
It is also possible, although with a low order of possibility,
that the two infrequent malignancies have arisen indepen-
dently of each other. In this case, it is difficult to determine
whether the bone lesion originated from multiple myeloma
or lymphoma, based only on imaging studies. 
In conclusion, it is important to think about lymphoid
malignancies of different pathology when an underlying
lymphoid neoplasm shows rapid progression. In addition,
considering the scarcity of the association between T-cell
lymphoma and multiple myeloma, detection and reporting
of new cases are of great value in the study of the potential
relationships of immunoregulatory derangements caused by
primary lymphoid tumors. 
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